Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26943968
DOI
10.1016/j.jneuroim.2016.01.018
PII: S0165-5728(16)30018-2
Knihovny.cz E-zdroje
- Klíčová slova
- Autoantibodies, Diagnosis, Myasthenia gravis, Radioimmunoprecipitation assay, Seronegative, Titin,
- MeSH
- autoprotilátky krev MeSH
- ELISA MeSH
- konektin imunologie MeSH
- lidé MeSH
- mezinárodní spolupráce MeSH
- myasthenia gravis krev diagnóza epidemiologie MeSH
- proteiny související s LDL-receptory imunologie MeSH
- radioimunoprecipitační analýza MeSH
- receptory cholinergní imunologie MeSH
- tyrosinkinasové receptory imunologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- autoprotilátky MeSH
- konektin MeSH
- LRP4 protein, human MeSH Prohlížeč
- MUSK protein, human MeSH Prohlížeč
- proteiny související s LDL-receptory MeSH
- receptory cholinergní MeSH
- tyrosinkinasové receptory MeSH
Myasthenia gravis (MG) is an autoimmune disease caused by antibodies targeting the neuromuscular junction of skeletal muscles. Triple-seronegative MG (tSN-MG, without detectable AChR, MuSK and LRP4 antibodies), which accounts for ~10% of MG patients, presents a serious gap in MG diagnosis and complicates differential diagnosis of similar disorders. Several AChR antibody positive patients (AChR-MG) also have antibodies against titin, usually detected by ELISA. We have developed a very sensitive radioimmunoprecipitation assay (RIPA) for titin antibodies, by which many previously negative samples were found positive, including several from tSN-MG patients. The validity of the RIPA results was confirmed by western blots. Using this RIPA we screened 667 MG sera from 13 countries; as expected, AChR-MG patients had the highest frequency of titin antibodies (40.9%), while MuSK-MG and LRP4-MG patients were positive in 14.6% and 16.4% respectively. Most importantly, 13.4% (50/372) of the tSN-MG patients were also titin antibody positive. None of the 121 healthy controls or the 90 myopathy patients, and only 3.6% (7/193) of other neurological disease patients were positive. We thus propose that the present titin antibody RIPA is a useful tool for serological MG diagnosis of tSN patients.
Bellvitge University Hospital Barcelona Spain
Department of Clinical Medicine University of Bergen Norway
Department of Neurology Medical University of Warsaw Poland
Faculty of Clinical Medicine Manheim University of Heidelberg Germany
Hadassah Hebrew University Medical Center Jerusalem Israel
Hellenic Pasteur Institute Athens Greece
Hellenic Pasteur Institute Athens Greece; Tzartos NeuroDiagnostics Athens Greece
Institute of Neurology Catholic University Rome Italy
Istanbul University Istanbul Turkey
Neurological Institute C Besta Milano Italy
Neurology Clinic Clinical Center of Serbia School of Medicine University of Belgrade Belgrade Serbia
Neurology Department Aeginition Hospital Athens Greece
Norway Department of Neurology Ullevaal University Hospital Oslo Norway
Raymond Poincaré Hospital Garches France
School for Mental Health and Neuroscience Maastricht University The Netherlands
The Cyprus Institute of Neurology and Genetics Nicosia Cyprus
Citace poskytuje Crossref.org
